LIQUICHEK ANA CONTROL, CENTROMERE PATTERN, MODEL 203

K984397 · Bio-Rad · DHN · Dec 18, 1998 · Immunology

Device Facts

• Record ID: K984397
• Device Name: LIQUICHEK ANA CONTROL, CENTROMERE PATTERN, MODEL 203
• Applicant: Bio-Rad
• Product Code: DHN · Immunology
• Decision Date: Dec 18, 1998
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 866.5100
• Device Class: Class 2

Intended Use

Liquichek ANA Control, Centromere Pattern is intended for use as an unassayed quality control to monitor indirect immunofluorescent testing of antinuclear antibodies (ANA).

Device Story

Liquichek ANA Control, Centromere Pattern is an in vitro diagnostic quality control product; prepared from human serum with added preservatives and stabilizers; contains 0.1% sodium azide. Provided in liquid form for convenience. Used by laboratory personnel to monitor the performance of indirect immunofluorescent testing for antinuclear antibodies (ANA). The control serves as a reference to verify the accuracy and reliability of the testing process; helps ensure consistent results in clinical diagnostics. Stored at 2-8°C.

Clinical Evidence

No clinical data; bench testing only.

Technological Characteristics

Human serum matrix; contains 0.1% sodium azide as a preservative; liquid form; stored at 2-8°C; 30-day open vial stability at 2-8°C.

Indications for Use

Indicated for use as an unassayed quality control to monitor indirect immunofluorescent testing of antinuclear antibodies (ANA) in clinical laboratory settings.

Regulatory Classification

Identification

An antinuclear antibody immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the autoimmune antibodies in serum, other body fluids, and tissues that react with cellular nuclear constituents (molecules present in the nucleus of a cell, such as ribonucleic acid, deoxyribonucleic acid, or nuclear proteins). The measurements aid in the diagnosis of systemic lupus erythematosus (a multisystem autoimmune disease in which antibodies attack the victim's own tissues), hepatitis (a liver disease), rheumatoid arthritis, Sjögren's syndrome (arthritis with inflammation of the eye, eyelid, and salivary glands), and systemic sclerosis (chronic hardening and shrinking of many body tissues).

Predicate Devices

• Kallestad Quantafluor Autoantibody Positive Control (K813592)

Submission Summary (Full Text)

{0}------------------------------------------------

K984397

Image /page/0/Picture/1 description: The image shows a date, "DEC 1 8 1998", printed in a simple, sans-serif font. The month is abbreviated as "DEC", followed by the day "18", and the year "1998". The text is clear and legible, with consistent spacing between the characters and words.

Image /page/0/Picture/2 description: The image shows the logo for Bio-Rad Laboratories, a company that manufactures and distributes products for the life science research and clinical diagnostics markets. The logo consists of the words "BIO-RAD" in white, bold letters against a black, rounded rectangle. The plus sign between "BIO" and "RAD" is a distinctive feature of the logo. The logo is simple and recognizable.

Bio-Rad Laboratories

e, California 92618-2017 ephone: [phone]

# 510(k) Summary

Submitter Bio-Rad Laboratories 9500 Jeronimo Road Irvine, CA [phone] Fax [phone]

Contact Person Elizabeth Platt

Date of Summary Preparation December 8, 1998

Device (Trade & Common Name) Liquichek ANA Control, Centromere Pattern

Classification Name Class II. 82DHN CFR 866.5100: Antinuclear Antibody, Indirect Immunofluorescent, Antigen, Control.

Devices to Which Substantial Equivalence is Claimed Kallestad Quantafluor Autoantibody Positive Control Sanofi Diagnostics Pasteur Chaska, Minnesota K813592

#### Statement of Intended Use

Liquichek ANA Control, Centromere Pattern is intended for use as an unassayed quality control to monitor indirect immunofluorescent testing of antinuclear antibodies (ANA).

{1}------------------------------------------------

Image /page/1/Picture/0 description: The image shows the logo for Bio-Rad Laboratories. The logo is in white text on a black background. The text is bold and sans-serif. The logo is enclosed in a rounded rectangle.

Bio-Rad Laboratories

Diagnostics Group 9500 Jeronimo Road Irvine, California 92618-2017 Telephone: [phone]

## Description of the Device

Liquichek ANA Controllee
preservatives and stablizers. This product is prepared from human serum with added preservatives and stabilizers. This product is provided in liquid form for convenience. This product contains 0.1% sodium azide as a provided in liqu

## Statement of How Technological Characteristics Compare to Substantial Equivalent
Device Device

A table is provided below comparing the similarities between the Bio-Rad Liquichek ANA Control, Centroller of Similanties belween the Bio-Rad Liquichek
claimed claimed.

| | Kallestad Quantafluor Autoantibody Positive<br>Control | Bio-Rad Liquichek<br>ANA Control, Centromere Pattern |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|
| Intended Use | Autoantibody positive control for Kallestad Quantafluor Fluorescent Autoantobody Test with mouse kidney, mouse stomach/kidney, Hep-2 cell line, or Crithidia luciliae substrates. | An unassayed quality control serum for monitoring indirect immunofluorescent testing of antinuclear antibodies (ANA). |
| Form | Lyophilized | Liquid |
| Matrix | Human Serum | Human Serum |
| Levels | Positive | Negative, Positive, High Positive |
| Storage | 2-8°C | 2-8°C |
| Analytes | ANA (Centromere, SSA, SSB, Scl-70, Sm, RNP, Spindle, Nucleolar)<br>AMA<br>ASMA<br>APCA<br>Anti-nDNA | ANA (Centromere Pattern) |
| Open Vial Claim | 6 weeks at 2-8°C<br>4 months at -20°C | 30 Days at 2-8°C |

{2}------------------------------------------------

Image /page/2/Picture/2 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" around the perimeter. Inside the circle is an abstract symbol that resembles a stylized eagle or bird in flight. The symbol is composed of three curved lines that form the wings and body of the bird.

DEC 18 1998

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

Elizabeth Platt Regulatory Affairs Supervisor Bio-Rad Laboratories 9500 Jeronimo Road Irvine, CA 92618

Re: K984397 Trade Name: Liquichek ANA Control, Centromere Pattern, Model 203 Regulatory Class: II Product Code: DHN Dated: December 8, 1998 Received: December 9, 1998

Dear Ms. Platt:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic OS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

{3}------------------------------------------------

Page 2

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at [phone].

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at [phone]. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number [phone] or at [phone] or at its internet address "http://www.fda.gov/cdrh/dsmamain.html"

Sincerely yours,

Steven Sutman

Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

Page 1 of 1

510(k) Number: _______________________________________________________________________________________________________________________________________________________________ Device Name: Liquichek ANA Control, Centromere Pattern

Indications for Use:

Liquichek ANA Control, Centromere Pattern is intended for use as an unassayed quality control to monitor indirect immunofluorescent testing of antinuclear antibodies (ANA).

#### (PLEASE DO NOT WRITE BELOW THE LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

(Concurrence of CDRH, Office of Device Evaluation)

| (Division Sign-Off) | |
|-----------------------------------------|---------|
| Division of Clinical Laboratory Devices | |
| 510(k) Number | 4984397 |

| Prescription Use | <div>/</div> | OR Over-The Counter Use |
|------------------|--------------|-------------------------|
|------------------|--------------|-------------------------|